FCGR3A and Miyoshi myopathy: RO7297089, a bispecific BCMA/CD16A-targeted ICE® intended to cause BCMA+ MM cell lysis via strong affinity interaction of CD16A and redirection of NK cell toxicity and macrophage phagocytosis, promotes antibody-dependent cell-mediated cytotoxicity (ADCC) and ADCP against myeloma cells effectively, as well as pharmacodynamic efficacy in cynomolgus monkeys (197).